August 29, 2011 Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe Tokyo, August 29, [removed]Astellas Pharma Inc. (Tokyo:4503, “As

First Page		Document Content
Date: 2011-08-26 02:56:51 Chemistry Incontinence Overactive bladder Solifenacin Urinary incontinence Astellas Pharma Urge incontinence Urinary retention Frequent urination Medicine Urology Muscarinic antagonists		August 29, 2011 Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe Tokyo, August 29, [removed]Astellas Pharma Inc. (Tokyo:4503, “As Add to Reading List Source URL: www.astellas.com Download Document from Source Website File Size: 52,34 KB Share Document on Facebook

	Vecchioli-Scaldazza C. · Morosetti C. · Berouz A. · Giannubilo W. · Ferrara V. Solifenacin Succinate versus Percutaneous Tibial Nerve Stimulation in Women with Overactive Bladder Syndrome: Results of a Randomized Con DocID: 1oiqJ - View Document
	solifenacin succinate compared to tolterodine tolterodine l-tartrate 4mg. tolterodine l-tartrate tolterodine base, enablex vs tolterodine la tolterodine, medcine tolterodine, tolterodine 4 mg, comparison of fesoterodine DocID: 1n0Q5 - View Document
	opera manuscript tolterodine. comparison of fesoterodine and tolterodine medrol dose pack tolterodine tolterodine conversion, tolterodine effects on potassium levels tolterodine excipients tolterodine xl, tolterodine tol DocID: 1gmcd - View Document
	Coll. Antropol: 243–248 Original scientific paper The Efficacy and Safety of Solifenacin in Patients with Overactive Bladder Syndrome Slavko Ore{kovi}1, Igor But2, Maja Banovi}1 and Marina [prem Gold{tajn1 DocID: 1cpY7 - View Document
	Omprövning av Toviaz, Vesicare och Emselex vid trängningsinkontinens Oktober 2014 Sammanfattning • Toviaz (fesoterodin) och Vesicare (solifenacin) kvarstår i DocID: 1c3ZZ - View Document